Ginkgo Bioworks DNA EPS (Diluted)
Discontinued — last reported Q4 '25
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Ginkgo Bioworks’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ginkgo Bioworks's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ginkgo Bioworks's EPS (diluted)?
- Ginkgo Bioworks (DNA) reported EPS (diluted) of -$1.42 in Q4 2025.
- How has Ginkgo Bioworks's EPS (diluted) changed year-over-year?
- Ginkgo Bioworks's EPS (diluted) increased by 27.6% year-over-year, from -$1.96 to -$1.42.
- What is the long-term trend for Ginkgo Bioworks's EPS (diluted)?
- Over 4 years (2021 to 2025), Ginkgo Bioworks's EPS (diluted) has grown at a 42.0% compound annual growth rate (CAGR), from -$1.39 to -$5.65.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.